Last reviewed · How we verify
NCT06820151
Exploring the Landscape of Injury and Repair in the Human Oesophagus
trial testing Sample collection in Perforations to the Oesophagus in 30 participants. Enrolling by invitation.
29 April 2026
Quick facts
| Lead sponsor | The Wellcome Sanger Institute |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 March 2022 |
| Primary completion | 29 April 2026 |
| Estimated completion | 29 April 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Sample collection — full drug profile →
Conditions studied
- Perforations to the Oesophagus — all drugs for Perforations to the Oesophagus →
Sponsor
The Wellcome Sanger Institute
Who can join
Adults 18 to 99, any sex, with Perforations to the Oesophagus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study limited to working with human tissue samples is to delineate the mechanisms defining appropriate oesophageal injury and repair and to use this information to understand how these rules are dysregulated and result in cancer formation in adult patients undergoing endoluminal vacuum therapy (EVT therapy) for the treatment of perforations to the oesophagus. The main question\[s\] it aims to answer are: * to gain a deeper understanding of the processes underlying tissue regeneration and repair in the oesophagus and upper gastro-intestinal tract following physical injury * to identify the similarities in the processes of regeneration and early carcinogenesis Participants will take part in the study during their usual EVT therapy schedule. Tissue brushings and pinch biopsies will also be taken.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06820151
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sample collection
Trials testing the same drug.
- NCT06634160 — Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozyg · recruiting
- NCT04894370 — Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma · Phase 2 · recruiting
- NCT05937815 — Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor · NA · unknown
- NCT05462366 — Omics Sequencing of Specimen Derived From Mother-Infant-Pairs · recruiting
- NCT04564183 — Advancing Prevention of Pulmonary Fibrosis · active not recruiting
Other The Wellcome Sanger Institute trials
Trials by the same sponsor.
- NCT06832150 — SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues · enrolling by invitation
- NCT06656767 — Somatic Mutation in Chronic Liver Disease · enrolling by invitation
- NCT06820294 — Retrospective WGS Study · enrolling by invitation
- NCT06584994 — Investigating the Role of Genetics in Disease Predisposition · enrolling by invitation
- NCT06497673 — Sanger Human Cell Atlasing Project · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06820151 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Wellcome Sanger Institute
- Last refreshed: 11 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06820151.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing